Next Article in Journal
Biofilm Growth on Simulated Fracture Fixation Plates Using a Customized CDC Biofilm Reactor for a Sheep Model of Biofilm-Related Infection
Previous Article in Journal
The Need for Multidisciplinarity in Modern Medicine: An Insight into Orthopaedic Infections
Previous Article in Special Issue
Cording Mycobacterium tuberculosis Bacilli Have a Key Role in the Progression towards Active Tuberculosis, Which is Stopped by Previous Immune Response
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Stewart et al. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms 2019, 7, 255

by
Erica Stewart
1,2,3,
James A Triccas
1,2 and
Nikolai Petrovsky
3,4,*
1
Discipline of Infectious Diseases and Immunology, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia
2
Charles Perkins Centre, The University of Sydney, Camperdown, NSW 2006, Australia
3
Vaxine Pty Ltd., Adelaide, SA 5042, Australia
4
Department of Endocrinology, Flinders University, Adelaide, SA 5042, Australia
*
Author to whom correspondence should be addressed.
Microorganisms 2022, 10(4), 757; https://doi.org/10.3390/microorganisms10040757
Submission received: 20 February 2022 / Accepted: 21 March 2022 / Published: 31 March 2022
The authors wish to make the following corrections to this paper [1]:
AS01E was mistakenly referred to as in emulsion form, as below:
One of the most advanced subunit vaccines, M72:AS01, was recently shown to have 54% efficacy in HIV-negative individuals with latent TB when administered intramuscularly in emulsion form (denoted M72:AS01E) [40]. The adjuvant in this vaccine, AS01, consists of a mixture of the TLR4 ligand, MPLA, together with the saponin fraction QS21 in a liposomal or emulsion formulation [41].
This should be changed to the correct version, as follows:
One of the most advanced subunit vaccines, M72:AS01, was recently shown to have 54% efficacy in HIV-negative individuals with latent TB when administered intramuscularly (M72:AS01E) [40]. The adjuvant in this vaccine, AS01, consists of a mixture of the TLR4 ligand, MPLA, together with the saponin fraction QS21 in a liposomal formulation [41].
The authors would like to apologize for any inconvenience caused to the readers by these changes and state that the scientific conclusions are unaffected. The original publication has also been updated.

Reference

  1. Stewart, E.; Triccas, J.A.; Petrovsky, N. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms 2019, 7, 255. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Stewart, E.; Triccas, J.A.; Petrovsky, N. Correction: Stewart et al. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms 2019, 7, 255. Microorganisms 2022, 10, 757. https://doi.org/10.3390/microorganisms10040757

AMA Style

Stewart E, Triccas JA, Petrovsky N. Correction: Stewart et al. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms 2019, 7, 255. Microorganisms. 2022; 10(4):757. https://doi.org/10.3390/microorganisms10040757

Chicago/Turabian Style

Stewart, Erica, James A Triccas, and Nikolai Petrovsky. 2022. "Correction: Stewart et al. Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms 2019, 7, 255" Microorganisms 10, no. 4: 757. https://doi.org/10.3390/microorganisms10040757

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop